GALWAY, Ireland – Medtronic plc (NYSE: NYSE:), a global healthcare technology company, has voluntarily initiated a field action for its MiniMed™ 600 and 700 series insulin pumps. Starting July 31, 2024, the company has been advising customers worldwide to monitor their pump’s built-in battery status alerts and alarms and to contact Medtronic for a pump replacement if they notice a significant decrease in battery life. This action follows customer reports and a comprehensive analysis indicating that physical impacts, such as drops or bumps, can damage internal electrical components, leading to reduced battery life.
The FDA has categorized this field action as a class I recall, the most serious type of recall where there is a potential for serious injury or death. Medtronic has received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the US that may be related to this issue from January 2023 to September 2024.
Medtronic’s updated customer notification includes guidance that even a single drop can affect the battery life and that the issue persists after changing the battery. The company advises users to be prepared to replace batteries promptly upon hearing the “Low Battery Pump” alarm and to always carry a spare set of batteries. Those experiencing unexpected battery depletion should contact Medtronic’s local support team for possible pump replacement.
Robert Vigersky, MD, Chief Medical Officer of Medtronic Diabetes, emphasized the company’s commitment to patient safety and continuous therapy, stating that Medtronic proactively notified impacted users due to the critical nature of pump functionality in diabetes management. The company provides 24/7 support to assist users experiencing battery depletion or other pump issues.
Medtronic is recognized for its efforts to transform diabetes care by enhancing access, integrating care, and improving outcomes. The company’s mission is to address challenging health problems and deliver innovative technologies that significantly impact patient lives.
This news is based on a press release statement from Medtronic plc.
In other recent news, medical technology company Medtronic has been the subject of multiple analyst notes. TD Cowen has maintained a Buy rating for the company, citing the anticipated growth in the Cardiac and Spinal Technologies (CST) and Spine sectors, driven by the company’s artificial intelligence-powered ecosystem, AiBLE. The firm also highlighted Medtronic’s recent…
Click Here to Read the Full Original Article at All News…
